drugset / Trial / NCT03990077
Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
NaSequentialOpen-labelTreatment
Summary
This is a phase I, open label, dose escalation study to evaluate tolerability, safety , pharmacokinetics and efficacy in patients with KRAS mutant NSCLC by using HL-085 and Docetaxel.
Timeline
- Start
- 2020-05-21
- Primary completion
- 2021-07-20
- Completion
- 2021-07-20
Outcome
Outcome not reported
Stopped (Business): “drug development strategy adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tunlametinib | Small molecule | — | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |